New prophylactics for migraine, targeting calcitonin gene-related peptide (CGRP), have recently emerged. Real-world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real-world setting, in order to determine which patients may be considered responders in clinical practice.

中文翻译：

---

用单克隆降钙素基因相关肽受体抗体erenumab治疗：一项真实的研究

最近出现了针对降钙素基因相关肽 (CGRP) 的新型偏头痛预防药。真实世界的数据对于全面了解治疗反应非常重要。我们在真实环境中评估了对 erenumab（一种单克隆 CGRP 受体抗体）反应的一致性，以确定哪些患者在临床实践中可能被视为反应者。